Navigating a New Frontier in Hemophilia: Evaluating the Utility of Evolving FVIIIa Mimetic Therapies to Address Unmet Needs

Hemophilia care is entering a new era with innovative factor and nonfactor therapies designed to overcome persistent challenges such as inhibitor development, frequent dosing, and treatment burden. This activity will explore available and emerging next-generation agents, including mechanisms of action, pharmacokinetics, dosing strategies, and clinical implications in patient care. Current and emerging data from pivotal trials will be discussed, along with practical considerations for integrating these therapies into clinical practice. Through interactive, case-based scenarios, learners will gain insights into patient selection, switching protocols, and individualized treatment planning, ensuring a patient-centered approach to hemophilia management.

Target Audience

This initiative is intended for hematology and hematology/oncology HCPs and other clinicians who provide care to PLwH.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Distinguish the structure and biophysical function of approved and next-generation FVIIIa mimetics and the related impact on PK/PD and dosing 
  • Evaluate clinical evidence on emerging FVIIIa mimetics as prophylaxis across varying hemophilia patient populations
  • Assess clinical considerations for integrating emerging FVIIIa mimetics into hemophilia management, including patient selection and switching from other therapies

Commercial Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
03/16/2026
Course expires: 
12/31/2026
Cost:
$0.00
Rating: 
0
March 20, 2026 Course Location: Portland, OR
United States

Manchester Grand Hyatt San Diego
1 Market Pl, San Diego, CA 92101

FACULTY
Glaivy Batsuli has a financial relationship: Advisor - Sanofi and Kedrion; Speaker - Octapharma.

Allison Wheeler, MD, MSCI has a financial relationship: Advisor - CSL Behring, Genentech, Octapharma, Cerus, SeraGene, Pfizer, Sanofi, Vega Therapeutics, Novo Nordisk.

Guy Young, MD has a financial relationship: Consultant – Takeda, Sanofi, Pfizer, Octapharma, Novo Nordisk, Hemab, Hema Biologics, Genentech, CSL, Biomarin, Alnylam.

STAFF/REVIEWERS
Dorothy Caputo, MA, BSN, RN, AKH President, has no financial relationships to disclose.
Rebecca Lakofsky, BSN, RN, AKH planner/reviewer, has no financial relationships to disclose.
Trish Brignoni, AKH Associate VP, has no financial relationships to disclose.
Stephanie S. Wenick, MPhil, Medical Writer, has served as a consultant medical writer for Nanoscope Therapeutics, Inc.
AKH and Catalyst Medical Education, LLC Planners and Reviewers, has no financial relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product 
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer 
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or register to take this course.